Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer
Authors:
- K. P. WeinfurtKWK. P. Weinfurt
- K. J. AnstromKAK. J. Anstrom
- L. D. CastelLCL. D. Castel
- K. A. SchulmanKSK. A. Schulman
- F. SaadFSF. Saad
- 13 March 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (6) , 986-989
Abstract
Background: Zoledronic acid reduces skeletal-related events associated with prostate cancer and has long-term efficacy in pain outcomes. Findings of treatment group differences in pain early in treatment are less reliable. We used a recently recommended analytic approach to examine the effect of zoledronic acid on pain. Materials and methods: In a trial of zoledronic acid (n = 214) versus placebo (n = 208), we used the Brief Pain Inventory to assess pain at baseline, 3 weeks, 6 weeks and every 6 weeks thereafter for a total of 60 weeks. We used a modified longitudinal rank test to determine whether clinically meaningful changes in pain were related to treatment group. Results: Seventy-six of 214 patients (35.5%) receiving zoledronic acid and 62 of 208 patients (29.8%) receiving placebo completed the 60-week visit (P = 0.22). In all 11 pain assessments, patients receiving zoledronic acid reported more favorable, clinically meaningful changes in pain scores. Overall, patients receiving zoledronic acid had a 33% chance of a favorable response, compared with 25% for patients receiving placebo (P = 0.04; 95% CI 0.5% to 15.6%). Conclusions: Zoledronic acid was more likely than placebo to be associated with clinically meaningful reductions in pain. Thus, zoledronic acid may help to avert the pain experienced by patients with progressing metastatic disease secondary to prostate cancer.Keywords
This publication has 18 references indexed in Scilit:
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerBMJ, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI: Journal of the National Cancer Institute, 2002
- Bisphosphonates for the relief of pain secondary to bone metastasesCochrane Database of Systematic Reviews, 2002
- What Is Clinically Meaningful: Outcome Measures in Pain Clinical TrialsThe Clinical Journal of Pain, 2000
- Interpreting treatment effects in randomised trialsBMJ, 1998
- Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scalingPain, 1996
- Combining dependent tests with incomplete repeated measurementsBiometrika, 1985
- The impact of pain on the patient with cancerCancer, 1984
- Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate ObservationsJournal of the American Statistical Association, 1984